Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
Adequate organ and bone marrow function
Confirmed diagnosis of CLL/SLL that meets iwCLL 2018 criteria for diagnosis and systemic treatment
Received at least 1 prior line of therapy for CLL/SLL that included a cBTKi and must have documented disease progression during treatment with, or after discontinuation of, the cBTKi
Participants with SLL must have measurable disease by computed tomography (CT) per iwCLL
You may not be if
Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment
Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment
Ongoing systemic corticosteroids ≥10 mg/day prednisone or equivalent
Previously treated with a BTK degrader or a noncovalent BTKi
Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment
Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment
